DC-CBi-22

N/A

Report date: 2023/11/09 10:00:49
NME

Base Information

Drug NameDC-CBi-22
Drug Alias NameDC-CBi-22
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionChromatin remodeling regulator CECR2 inhibitors
TargetsChromatin remodeling regulator CECR2
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A